Healthcare Industry News:  Transdermal 

Devices Drug Delivery Personnel

 News Release - August 2, 2007

Vyteris Announces Appointment of Anthony J. Cherichella as Chief Financial Officer

Hiring Reflects Strengthening of Financial and Investor Relations Programs

FAIR LAWN, N.J.--(HSMN NewsFeed)--Vyteris, Inc. (OTCBB: VYHN ) announced today the appointment of Anthony J. Cherichella as chief financial officer and principal accounting officer, overseeing financing, forecasts and investor relations.

"Tony brings an enormous wealth of public healthcare company experience which will prove an integral part of our efforts in moving towards commercialization of our products," said Timothy J. McIntyre, president and chief executive officer of Vyteris. "A financial executive with his background strengthens our management team and delivers on our commitment enhance our relationship with present and future Vyteris shareholders and the investment community."

Most recently, Cherichella, 39, was the chief financial officer and acting president for Cardinal Health's Healthcare Marketing Services unit based in Wayne, NJ, a position he held from 2002 to the present. In that capacity, he had overall responsibility for establishing and managing financial budgets and forecasts, evaluating acquisitions and exploring strategic alternatives for this unit of Cardinal Health.

Prior to that, he served at BLP Group Companies from 2000-02, where he was chief financial officer, executive vice president, secretary and treasurer. Before that, he served as a senior audit manager for Andersen LLP from 1990-2000.

"I am grateful for the opportunity to come in at such an exciting time for Vyteris where we are poised to fully commit towards the commercialization and sale of LidoSite and provide pain relief for patients, and also future opportunities to increase value for our shareholders," Cherichella said. "This is a tremendous opportunity and one I look forward to."

Cherichella received his Bachelor of Science degree in Accounting from Fairleigh Dickinson University. He is a certified public accountant and a member of the American Institute of Certified Public Accountants. He serves on the Board of Trustees of Caldwell College of New Jersey as well as on its Finance Committee. He is married with two daughters.

About Vyteris, Inc.

Vyteris, Inc., a wholly owned subsidiary of Vyteris Holdings (Nevada), Inc. (OTCBB: VYHN ), is the maker of the first active drug delivery patch to receive marketing clearance from the U.S. Food and Drug Administration (FDA). Vyteris' proprietary active Transdermal drug delivery (iontophoresis) technology delivers drugs comfortably through the skin using low-level electrical energy. This active patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that can result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration. Vyteris' first product, LidoSite®, which provides dermal analgesia prior to venipuncture (IV catheter insertions, blood draws, etc.) and superficial dermatological procedures, was the first FDA approved active patch. For more information, please visit our website at www.vyteris.com.

Forward-Looking Information

This press release contains forward-looking statements (within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended). When used in this press release, the words "anticipate," "believe," "estimate," "will," "plan," "seeks," "intend," and "expect" and similar expressions identify forward-looking statements. Although we believe that our plans, intentions, and expectations reflected in any forward-looking statements are reasonable, these plans, intentions, or expectations may not be achieved. Our actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied, by the forward-looking statements contained in this press release. Important factors that could cause actual results to differ materially from our forward looking statements are set forth in the Company's periodic reports on Forms 10-KSB and 10-QSB, including under the heading "Risk Factors." All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in the Company's periodic reports. Except as required by federal securities laws, we are under no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.


Source: Vyteris

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.